Welcome to the

Picture

Our lab devises methods to selectively kill cancer cells by better understanding apoptotic cell death
​
Alongside the lab's mission, Dr Anthony Letai is also the president of The Society for Functional Precision Medicine, which works to improve patient care and outcomes by facilitating implementation of functional assays into clinical care.

Our Bulletin Board

 Dana-Farber video of how BCL-2 research helps patients at Dana-Farber.

Dana-Farber’s Momentum of Discovery – Featuring Drs. Anthony G. Letai and Jacqueline S. Garcia. 

Acquired resistance targeted functionally in AML

The researchers highlighted the effectiveness of a functional precision medicine approach, called dynamic BH3 profiling (DBP), in identifying targeted therapy for highly aggressive relapsed acute myeloid leukemia. The technique can measure the increase in mitochondrial priming, which signifies a higher potential for apoptosis. DBP can identify drugs with new or persistent activity in resistant tumors for the development of targeted in vivo therapeutic strategies.

https://doi.org/10.1158/2643-3230.BCD-24-0001
Happy Holidays from the Letai to you. Pictures from our annual Holiday Party.
Salma Parvin has just published a great paper on CLL https://shorturl.at/knqK0. Identifiable subsets of CLL (incl IgHV unmutated) are less primed for apoptosis, less mature, and - importantly!- sensitive to FLT3 inhibition! Please check it out. 
The Letai Lab - Targeting Cancer Cell Death